GPT Healthcare Limited , a prominent player in the healthcare sector, has announced its financial results for the second quarter, along with an interim dividend declaration. The company's performance shows a mixed picture, with revenue growth but a decline in profitability.

Financial Performance

GPT Healthcare reported a decrease in net profit for Q2, while simultaneously achieving an increase in revenue. Here's a breakdown of the key financial metrics:

The company's revenue showed a notable increase of 13.33% year-over-year, rising from ₹1.05 billion to ₹1.19 billion. However, this top-line growth did not translate into higher profitability. Net profit declined by 28.38%, from ₹148.00 million in the previous year to ₹106.00 million in the current quarter.

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) also saw a slight decrease, falling from ₹234.20 million to ₹227.40 million. Consequently, the EBITDA margin contracted from 22.17% to 19.13%, indicating some pressure on operational efficiency.

Dividend Declaration

GPT Healthcare's Board of Directors has recommended an interim dividend of ₹1 per share. This represents a 10% dividend on the face value of the equity shares, which stand at ₹10 each.

Key details of the dividend declaration include:

• Dividend Rate: 10% (₹1 per share)
• Record Date: November 14, 2025
• Expected Payment Date: On or before December 7, 2025

Management Changes

The company also announced significant changes in its leadership structure:

1. Dr. Om Tantia, previously the Managing Director, has been elevated to the position of Chairman and Managing Director, effective November 8, 2025.
2. Mr. Shree Gopal Tantia, formerly a Non-Executive Director, has been appointed as the Vice Chairman of the company, also effective from November 8, 2025.

These management changes suggest a strategic realignment at the top level, which could influence the company's future direction and operations.

GPT Healthcare's mixed Q2 results, coupled with the dividend announcement and management restructuring, present a complex picture for investors and stakeholders. While the revenue growth is encouraging, the decline in profitability may warrant closer attention to the company's cost management and operational strategies in the coming quarters.

GPT Healthcare Ltd, a prominent player in the healthcare sector, has announced significant changes to its board composition and corporate structure following the unfortunate demise of its Executive Chairman, Shri Dwarika Prasad Tantia.

Board Appointment and Restructuring

The company's board of directors, in a meeting held on September 24, 2025, approved the appointment of Mr. Shree Gopal Tantia as an Additional Non-Executive Non-Independent Director. Mr. Tantia, aged over 60 years, brings with him a wealth of experience spanning more than four decades in the infrastructure and civil construction sectors.

Corporate Social Responsibility Committee Reconstitution

In light of the recent changes, GPT Healthcare has also reconstituted its Corporate Social Responsibility (CSR) Committee. The newly formed committee will be chaired by Dr. Om Tantia, with Dr. Aruna Tantia and Dr. Tapti Sen serving as members.

Articles of Association Amendments

The board has approved alterations to the company's Articles of Association, subject to shareholder approval. These changes include:

• Deletion of certain articles related to the initial public offering (IPO) process
• Modifications to the appointment of the board chairperson

Postal Ballot for Shareholder Approval

GPT Healthcare has initiated a postal ballot process to seek shareholder approval for two key matters:

1. The appointment of Mr. Shree Gopal Tantia as a Non-Executive Non-Independent Director
2. The proposed alterations to the Articles of Association

Leadership Profile

Mr. Shree Gopal Tantia, a commerce graduate, is recognized as one of the promoters of the GPT Group Companies. His extensive experience in the infrastructure and civil construction sector is expected to bring valuable insights to the company's operations.

Regulatory Compliance

The company has assured that Mr. Tantia is not debarred from accessing capital markets or restrained from holding directorship positions by any regulatory authority, including the Securities and Exchange Board of India (SEBI).

These developments mark a significant transition period for GPT Healthcare as it adapts to new leadership while maintaining its commitment to corporate governance and shareholder interests.